Company: SMNR
Filing Date: 2025-08-12
Form Type: S-4/A
Source: 0001193125-25-178821
Chunk: 60

Company: Semnur Pharmaceuticals, Inc.
Filing Date: 2025-08-12
Form: S-4/A
Chunk 60
---
 86,625 |     |           |   0.9 | % |     |                 |     86,625 |     |           |   1.0 | % |
| Consultant Shares                                                      |     |               | 30,500,000 |     |           |  91.0 | % |     |                | 30,500,000 |     |           |  91.0 | % |     |                | 30,500,000 |     |           |  91.0 | % |     |                | 30,500,000 |     |           |  91.0 | % |     |                 | 30,500,000 |     |           |  91.0 | % |
| Total Number of Shares**                                               |     |               | 33,510,747 |     |           | 100.0 | % |     |                | 33,499,812 |     |           | 100.0 | % |     |                | 33,488,877 |     |           | 100.0 | % |     |                | 33,477,942 |     |           | 100.0 | % |     |                 | 33,467,008 |     |           | 100.0 | % |

| ** | Excludes 8,235,378 of shares underlying public warrants, 14,622 of shares underlying public warrants underlying public units, and 510,000 of shares underlying private warrants underlying the Denali private placement units because such warrants are expected to remain outstanding after the Business Combination since their exercise is not contingent on the consummation of the Business Combination. Other potential sources of dilution that may occur following the consummation of the Business Combination include |

17

| 50,000,000 of shares associated with Semnur option holders and 30,500,000 of shares of Semnur consultant fees paid in shares. |

The calculation in this footnote (2), used as the denominator for each book value per share as of March 31, 2025, as adjusted, excludes shares of common stock issued as Merger Consideration to the former securityholders of Semnur from the denominator of the per-share calculation as well as certain securities that could be potential sources of dilution after the closing of the Business Combination, including: 8,235,378 shares underlying public warrants and 510,000 shares underlying private warrants forming